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Abstract
Purpose: We examined factors associated with antiretroviral therapy (ART) adherence among 
transgender women living with HIV (TWLWH).
Methods: We used combined data from the 2009 to 2013 cycles of Medical Monitoring Project 
(MMP), an HIV surveillance system designed to produce nationally representative estimates of the 
characteristics of HIV-infected adults receiving HIV medical care in the United States. Rao-Scott 
chi-square tests and multivariable logistic regression were used to identify factors associated with 
dose adherence (defined as taking 100% of prescribed ART doses in the past 3 days).
Results: Among TWLWH who reported current antiretroviral therapy use, an estimated 80.5% 
self-reported dose adherence. Multivariable factors independently associated with lower (<100%) 
dose adherence were younger age (30-39 vs. 40 and over), not having health insurance coverage, 
depression, lower self-efficacy to take medication as prescribed, and having greater than one daily 
ART dose.
Conclusion: Our findings suggest several ways to potentially improve ART adherence of 
TWLWH including tailoring efforts to address the needs of TWLWH under age 40, increasing 
access to health insurance coverage, addressing mental health morbidities, building skills to 
improve medication adherence self-efficacy, and simplifying ART regimens when possible.
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Introduction
Transgender women are at high risk for HIV infection. Systematic reviews consistently show 
high HIV prevalence rates (19.1 - 27.7%) among transgender women in the United States as 
well as globally.1-3 Antiretroviral therapy (ART) has been proven not only to improve health 
outcomes for persons living with HIV (PLWH), but also to reduce the risk of transmission to 
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HIV-negative partners.4 It is important that transgender women living with HIV (TWLWH) 
access ART and adhere to their ART regimens to ultimately suppress their HIV viral load.
Mizuno and colleagues5 analyzed a nationally representative sample of PLWH in HIV care 
in the United States (U.S.) who were surveyed in the 2009 to 2011 cycles of Medical 
Monitoring Project (MMP). Their study showed that the percentage of PLWH prescribed 
ART was similar across gender groups, but transgender women were significantly less likely 
than cisgender men to report 100% dose adherence (78% vs. 87%), and less likely to achieve 
sustained viral suppression (i.e., having undetectable viral load or <200 copies/mL at all 
tests during the past year), 51% vs. 61%. Poor adherence to ART among TWLWH has also 
been reported elsewhere.6-8 Few studies have sought to identify factors associated with 
medication adherence among TWLWH, and these studies were limited by small (n=22-59), 
convenience samples of TWLWH.8,9
To contribute to the sparse literature on ART adherence among TWLWH, we analyzed data 
from the 2009-2013 cycles of MMP, which include information on more than 250 TWLWH 
in HIV care in the United States. We sought to characterize the following: the prevalence of 
ART adherence, the association between adherence and viral suppression, and factors 
associated with adherence among TWLWH.
Methods
MMP Design and Data Collection
We analyzed combined data from the 2009 - 2013 cycles of MMP, an HIV surveillance 
system designed to produce annual nationally representative estimates of behavioral and 
clinical characteristics of HIV-infected adults receiving medical care in the United States. 
MMP methods, including weighting procedures and response rates, have been described in 
detail elsewhere.10 Briefly, the 2009–2013 MMP cycles used a three-stage, probability-
proportional-to-size sampling method. First, U.S. states and one territory were sampled, then 
facilities in those areas providing outpatient HIV care, and finally, eligible HIV-infected 
patients. Eligible persons were HIV-infected, age 18 years or older, and had received 
medical care in participating facilities between January and April in the cycle year for which 
they were sampled. All 23 sampled health jurisdictions participated in every cycle. The 
facility response rate ranged from 76% to 85% and the patient response rate ranged from 
52% to 56%. Matched interview and medical record abstraction data for all respondents 
were collected June 2009 through May 2014.
Respondents were asked to report their sex at birth and their current self-identified gender. 
Those who self-identified as transgender or those whose sex at birth and current self-
identified gender were discordant were categorized as transgender. Transgender persons 
were further categorized into transgender women (male-to-female transgender, i.e., sex at 
birth was male and current gender was transgender or female) and transgender men (female-
to-male transgender, i.e., sex at birth was female and current gender was transgender or 
male). Thirteen persons were excluded because information needed to classify into one of 
the above categories was missing. Because the number of transgender men was too small 
(n=35) to conduct comparative analyses, we focused on transgender women. Further, 
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because assessment of ART adherence was our primary focus, our analytic sample was 
limited to 258 transgender women who reported current ART use.
Ethics Statement
In accordance with guidelines for defining public health research,11 the Centers for Disease 
Control and Prevention (CDC) determined MMP was public health surveillance used for 
disease control, program, or policy purposes. Local institutional review board approval was 
obtained at participating states, territory, and facilities when required. Written or verbal 
informed consent was obtained from all interviewed participants.
Analytic Methods
We followed the methods used in Beer et al.12 that examined MMP data to identify factors 
associated with ART adherence among all adult PLWH in care. We used self-reported 
adherence measures developed by the AIDS Clinical Trials Group.13 Dose adherence was 
defined as taking 100% of prescribed ART doses in the past 3 days, schedule adherence was 
defined as taking all ART doses according to one’s prescribed schedule in the past 3 days 
(e.g., 2 times a day), and instruction adherence was defined as following all special 
instructions for taking their antiretroviral medicines in the past 3 days (e.g., take with food). 
Instruction adherence was only measured among persons with special instructions for taking 
their antiretroviral medicines. We assessed the associations between these adherence 
measures and a measure of viral suppression abstracted from medical records defined as 
participant’s viral load at last test being undetectable or <200 copies/mL.
We then assessed bivariate associations between dose adherence and many of the same 
potential correlates assessed in Beer et al.12 (Table 1), using Rao-Scott chi-square tests.14 
Health insurance coverage in the past 12 months was assessed using patient response about 
health care coverage and ways for which ART medications were paid, and was defined as 
“having private or public health insurance or Ryan White/AIDS Drug Assistance Program 
coverage” versus “uninsured.” Depression in the past 2 weeks was measured using patient 
response to the Patient Health Questionnaire (PHQ-8),15 which consists of eight of the nine 
criteria on which the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
(DSM-IV-TR)16 diagnosis of major or other depressive disorders are based. Stimulant use in 
the past 12 months was defined as self-reporting injection or non-injection use of 
methamphetamines, other amphetamines, cocaine, or crack. Binge drinking in the past 30 
days was defined as self-reporting five or more drinks in one sitting. “One daily ART dose” 
was defined as self-reporting a single daily ART dose (either a single tablet or multiple 
tablets taken concurrently). Participants also reported the degree to which they were 
bothered by side effects. Psychosocial variables included self-efficacy (a person’s belief in 
her own ability) to take medication as prescribed, belief that medication has a positive effect 
on health, belief that non-adherence will result in resistance to ART, and satisfaction with 
social support (all single-item measures). Due to small cells in some of the response 
categories, age was categorized into “18-29” “30-39” and “40 and over” and race was 
categorized into “black or African American” versus “not black/African American.”
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Lastly, we conducted multivariable logistic regression analysis to identify factors 
independently associated with dose adherence, using a backward elimination modeling 
strategy with p<0.10 inclusion and p<0.05 retention criteria. All analyses accounted for 
clustering, unequal selection probabilities,17 and patient and facility nonresponse 18,19 by 
using SURVEY procedures in SAS 9.3 (SAS Institute Inc., Cary, NC) and SAS-callable 
SUDAAN 10.0.1 (RTI International, Research Triangle Park, NC). The SAS and SUDAAN 
procedures included sampling weights and strata and cluster information to account for the 
complex survey design of MMP.
Results
Among TWLWH who reported current ART use in the United States, almost half were black 
or African American (47%) and their mean age was 43.3 years. They were predominantly 
poor but over 80% had some form of health insurance coverage. About a quarter (24%) 
reported symptoms consistent with major or other depression, 13% reported stimulant drug 
use, and 19% reported recent binge drinking. A little over a third (34%) reported taking one 
daily ART dose (Table 1).
Eighty percent reported dose adherence, 71% reported schedule adherence, 67% reported 
instruction adherence, and 56% reported being adherent to all three measures (Table 2). All 
measures of ART adherence were positively associated with viral suppression (Prevalence 
Ratio [PR]>1.00) at last test and statistical significance (p<0.05) was observed for all 
associations except for instruction adherence.
Table 1 reports the results of bivariate analyses of the association between dose adherence 
and our examined covariates. Factors associated with lower (<100%) dose adherence were 
younger age, homelessness, incarceration, no health insurance coverage, depression, 
stimulant drug use, binge drinking, lower self-efficacy to take medication as prescribed, and 
not believing the negative effect of non-adherence (i.e., the virus may become resistant to 
ART) (p<0.05). Having one daily ART dose (vs. 2 or more daily ART doses) was marginally 
(p<0.1) associated with dose adherence. Race, educational attainment, poverty level, being 
bothered by side effects, belief that medication has positive effects on health, satisfaction 
with social support, and time since HIV diagnosis were not associated with dose adherence.
In multivariable analysis (Table 3), TWLWH age 30-39 compared to those age 40 and over 
(adjusted Prevalence Ratio [aPR] 0.76, 95% Confidence Interval [CI 0.63-0.92]), those with 
no health insurance coverage (aPR 0.80 [0.66-0.97]), those who were depressed (aPR 0.82 
[0.70-0.95]), and those who had lower self-efficacy to take medication as prescribed (aPR 
0.59 [0.42-0.84]) were independently less likely to report dose adherence. TWLWH who 
reported having one daily ART dose were independently more likely to report dose 
adherence.
Discussion
Among TWLWH who reported current ART use, an estimated 80.5% self-reported dose 
adherence, and those who were dose adherent were almost 70% more likely to achieve viral 
suppression at last test than those who were not adherent. Our multivariable analysis 
Mizuno et al. Page 4
LGBT Health. Author manuscript; available in PMC 2019 August 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
identified correlates of lower (<100%) dose adherence among TWLWH that are consistent 
with findings from a nationally representative sample of HIV-infected adults in care12 
including younger age (30-39 vs. 40 and over), depression, having greater than one daily 
ART dose, and lower self-efficacy to take medication as prescribed. Depression and 
adherence self-efficacy have been found to be strongly associated with ART adherence in 
studies not specifically focused on transgender women.20 Another study found that 
transgender women, compared to other HIV-infected persons, reported lower self-efficacy to 
integrate treatment regimens into their daily lives.6 The same study also found that this 
variable explained the difference in adherence rate between transgender women and others, 
suggesting that imparting skills to integrate treatment into one’s daily routine may be 
particularly important for TWLWH. Our findings lend further support to the provision of 
mental health care and medication adherence skills-building as actionable points of 
intervention for improving adherence among TWLWH. The finding on having one daily 
ART dose also suggests that health care providers may facilitate improvements in adherence 
by simplifying ART regimens when possible for their transgender patients.
We also found an association between the lack of health insurance, or medication coverage, 
and lower dose adherence in the multivariable model. Not having coverage was associated 
with a 20% reduction (aPR=0.80 [95% CI: 66%-97%]) in the prevalence of dose adherence, 
suggesting that expansion of health insurance (private or public), or medication coverage 
through the Ryan White Program or the AIDS Drug Assistance Program, may be needed to 
improve adherence among TWLWH. Health insurance coverage was not tested in previous 
studies that examined correlates of adherence among TWLWH,6,8,9 however, our finding is 
reasonable because those who are uninsured are unlikely to be able to afford HIV 
medications on a consistent basis. Studies of medication adherence for other diseases (e.g., 
cardiovascular diseases, diabetes, schizophrenia), in other populations, demonstrate 
associations between adherence and the level of patient out-of-pocket expenses, copayment, 
prescription drug coverage, and type of insurance plan.21-27 The data and findings illustrate 
how financial burden associated with medication might negatively affect adherence.
Limitations
This analysis has several limitations. First, our data were cross-sectional, and thus no causal 
inference can be made regarding associations between dose adherence and its correlates. 
Second, we used self-reported adherence measures that could overestimate adherence.28 
However, we did find a significant and positive association between dose adherence (in the 
past 3 days) and the biological measure of viral suppression at last test, and this association 
supports the validity of the self-reported adherence measure. Third, MMP is not a specific 
study of transgender persons, and thus did not collect other data that may be relevant for 
adherence among transgender persons. For example, we could not explore findings from a 
study reporting how stress appraisal of transphobic experience, importance of gender 
affirmation, and adherence to hormone therapy were significantly associated with ART 
adherence among TWLWH.9 Fourth, the precision of our estimates was limited due to small 
sample size. Lastly, we did not conduct analyses for transgender men (female-to-male 
transgender persons) because sample size was too small, even after combining five cycles of 
MMP data.
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Conclusion
Analysis of MMP data enabled identification of correlates of dose adherence among 
TWLWH using a large, national sample of HIV-infected adults receiving HIV care in the 
United States. Our findings support those of a broader study of PLWH,12 and suggest several 
potential ways to improve adherence of TWLWH at the population level including tailoring 
efforts to address the needs of TWLWH under age 40, addressing mental health morbidities, 
simplifying ART regimens if possible and building skills to improve adherence self-efficacy. 
In addition, we identified health insurance coverage as a structural factor that might be 
leveraged to improve adherence among this population. Future research should identify 
additional specific strategies that will reduce disparities among TWLWH.
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